Clinical research, CRO, phase 1 studies - global offices at US, UK, India, Belgium and France

Veeda @ Glance, Global Full-service Phase I and IIa clinical research, CRO

clinicalresearchandcro — Fri, 08 Oct 2010 06:30:51 +0000

Veeda Clinical Research, is a global full-service Phase I and IIa clinical research and trials, contract research organizations (CRO), clinical research studies by expert’s Clinical research professionals in Japan, India, UK and Belgium.

Our Expertise

Diabetology
Glucose-Clamping
Renal-impairment Studies
Japanese-Bridging Studies
Elderly Studies
Female studies
CNS and Pain
Women’s Health
Cardiovascular
Respiratory
Immunology
Infectious Disease
Anaesthetics
Gastro-Intestinal
Elderly Studies
Renal Disease
Oncology
Dermatology
Laboratory services
Bioavailability Bioequivalence

Why choose Veeda?
•   Largest and most experienced Phase 1 CRO in India
•   Independent and entirely focused on clinical research
•   Over 700 studies completed to date
•   Over 160 studies completed for USFDA submission
•   4 successful FDA audits
•   Over 160 methods offered through our fully-complaint GLP laboratories
•   An established Biometrics team in Belgium and India
•   Collaborations with international hospitals and universities

To know more about our services please visit our website Veeda Asia

Veeda Oncology – Global Oncology Company, Over 20 years of phase 1 clinical trials experience in the oncology

clinicalresearchandcro — Thu, 18 Mar 2010 05:55:17 +0000

Veeda Oncology is a global oncology company and a member of the Veeda CR family of companies. While Veeda Oncology is a growing company, our management team has over 20 years of phase 1 clinical trials experience in the oncology field with facilities located in the US, Europe and India. The company is a full service oncology CRO for Phase I through Phase IV studies with the unique capability of providing rapid and strong global patient accrual with an effective cost structure.

Veeda Oncology is a vibrant Anglo/India CRO which brings together 20 years of clinical research expertise with the intellectual ability and tireless work ethic of the East. Veeda oncology offers oncology phase 1 trials services

In addition to Academic Phase I Oncology Units, Veeda Oncology has established a Network of 5 Community based Phase I sites.
•   Access to over 30,000 new Oncology patients per year
•   Ongoing experience in the development of new molecular,
•   targeted, biologic and pharmaceutical therapies
•   Oncology Experience in:
o   Bioavailability/Bioequivalent studies
o   Pharmacokinetic sampling
•   Outpatient facilities with extended hours to accommodate trial needs

View Veeda oncology case study and to know more information about veeda oncology services please feel free to contact US.

Oncology Clinical Trials Landscape and Its Impact on Investigative Sites

clinicalresearchandcro — Fri, 12 Mar 2010 11:35:28 +0000

This webinar by Kenneth A. Getz will focus on the major trends challenging drug development and strategies that pharmaceutical and biotech companies can/are implementing to address these challenges. Key challenges that will be highlighted are:

•   Ongoing stagnation of drug development innovation
•   Decrease in trial pipelines within pharma/biotech companies
•   Growing globalization of clinical trial sites
•   Impact of lowered reimbursement on sites ability to conduct clinical research
•   High levels of investigative site inefficiency and poor quality
•   Increasing level of complexity in clinical trial design
•   Poor public trust in clinical research professionals

The following individuals will find this session very informative:
Pharmaceutical/Biotech clinical operations teams, Outsourcing, investigative site personnel, Principal Investigators, Research Coordinators.

Kenneth A. Getz, M.B.A. – Senior Research Fellow

Kenneth A. Getz is a senior research fellow at the Tufts CSDD. Considered an expert on the investigative site and CRO markets, R&D management, ECT solutions adoption and clinical research volunteerism, he is a wellÂ¬known speaker at conferences, university symposia, and corporate programs and has published extensively in peer review journals and books. Mr. Getz is the founder and chairman of CISCRP, and serves on the Clinical Trials Transformation Initiative board of directors. He is on the editorial boards of the DIA Journal, Controlled Clinical Trials and Research Practitioner and writes a regular column for Applied Clinical Trials. He holds an MBA from the J.L. Kellogg Graduate School of Management at Northwestern University and a bachelor’s degree, Phi Beta Kappa, from Brandeis University. Mr. Getz worked for over seven years in management consulting, where he assisted biopharmaceutical companies in planning and implementing drug development strategies. He is also the founder and former CEO of Center Watch.

Measuring Cardiac Function in the Phase I Unit – What is Possible?

clinicalresearchandcro — Fri, 05 Feb 2010 06:46:29 +0000

There is an increase in demand for conducting Clinical Research in Asian and South East Asia We invite you to attend this webinar by Dr Maurice Cross to understand the technologies available for the monitoring of cardiovascular function in the Phase I Unit and the different ways in which they may be deployed to obtain early pharmacodynamic information.

In the pre-clinical arena, everything is possible. Invasion is not an issue.
•   Basic cellular electrophysiology
•   The Langendorff
•   Acute anaesthetised studies
•   Instrumented animals

On translating to the human, and especially the normal volunteer, there is an understandable reluctance to conduct invasive studies. But sometimes, heart-rate, blood pressure and the electrocardiogram are not enough.

At Veeda we have specialized in maximizing the information from cardiovascular studies. This webinar reviews the available techniques and our experience with them. REGISTER NOW

Dr Maurice Cross, Group Medical Director, Veeda

Maurice Cross graduated in Medicine from Aberdeen University in 1972 and began a career in academic medicine as a Medical Research Council Junior Research Fellow at Northwick Park Hospital. After a training period in Cardiology he entered the Offshore Oil Industry as physician to COMEX diving, focusing on the physiological aspects of putting man under the sea at increasing depth. This start sealed his career as an experimental physician/pharmacologist and, after a second period as an academic at Newcastle University, he founded Phase I Clinical Trials Unit in 1987 in Plymouth.

Since then, Maurice has been associated with Phase I Clinical Trials Unit Ltd. with focus on the problems of early drug development either from a basic science or early clinical perspective. He led Phase I Clinical Trials Unit Ltd. into a merger with an Indian CRO and continues to influence the Veeda Clinical Research Group in his role as Director.

For more information about Measuring Cardiac Function in the Phase I Unit – What is Possible?, please click here

for on demand for this webinar click here

Laboratory services India – Premier Bio-analytical facility and services

clinicalresearchandcro — Fri, 05 Feb 2010 06:35:05 +0000

Veeda Clinical Research Laboratory located in Ahmedabad, India is a Premier Bio-analytical facility offering bio-analytical services to the Pharmaceutical and bio tech Sector.

All of our services are designed to support studies conducted internally in our clinics, as well as being true stand-alone services for external studies, whether pre-clinical, or single/multi site clinical studies.

Our analytical management team have collectively more than 45 years of bio-analytical experience including method transfer, validation and de novo method development for generic compounds and NCE molecules. Our analytical personnel comprises of some of the most experienced analytical staff in India.

For more information about laboratory services in India please click here

Oncology (Cancer) clinical Research and Trials for biotechnology and pharmaceutical industries

clinicalresearchandcro — Wed, 03 Feb 2010 06:10:40 +0000

Veeda Oncology is a vibrant Anglo/India CRO which brings together 20 years of clinical research expertise with the intellectual ability and tireless work ethic of the East. From First-in-Man studies to large scale Bioequivalence/Bioavailability comparator studies Veeda Clinical Research offers a fully integrated package to meet your early clinical development needs.

We provide phase 1 and phase II clinical trials for cancer research and deliver cost effective research solutions for biotechnology oncology and pharmaceutical oncology. Veeda CR can take your compound from pre-clinical development to proof of concept in the most timely, cost effective manner.

Veeda Oncology is part of the Veeda Group that includes Veeda Clinical Research, which is a leading CRO specializing in the early oncology research, clinical development of drugs with state of the art clinical pharmacology units in the UK, Europe and India, fully accredited GLP Laboratories and an established Biometrics team in Belgium and India.

View our Oncology phase 1 trials, oncology experience, company profile, Oncology case studies, Access to Oncology Patients services.

Phase 1 Clinical research for drug development ser vices in Japan by Veeda Clinical research

clinicalresearchandcro — Tue, 02 Feb 2010 11:26:53 +0000

Veeda Clinical Research provide the Global Pharmaceutical Industry with new locations for effective drug development – that is what Veeda is all about

Veeda Clinical Research is a leading CRO specializing in the early clinical development of drugs. With state of the art clinical pharmacology units in the UK and India, fully complaint GLP Laboratories and an established Biometrics team in Belgium and India, Veeda is able to offer clients a full range of phase I and IIa services. In addition, Veeda maintains an extensive database of volunteers from which to accrue appropriate subjects in a timely fashion.

For more information about clinical research and new drug development in Japan please visit Veeda Asia

Expert Biometrics group for pharmaceutical, biotech and medical device companies

clinicalresearchandcro — Tue, 02 Feb 2010 09:05:51 +0000

Veeda Biometrics is dedicated to providing biometrics services like Clinical Data Management, Statistical Analysis and Programming, Medical Writing by our expert biometrics group for pharmaceutical, biotech and medical device companies at India and Belgium.

Veeda Clinical Research’s Biometrics unit has divisions in both Europe and in India. With 18 years of experience in all phases of clinical research Veeda CR specialises in providing high quality data management, statistics and Medical writing in accordance with global regulatory standards.

Veeda Clinical Research is a leading CRO specializing in the early clinical development of drugs. With state of the art clinical pharmacology units in the UK and India, fully complaint GLP Laboratories and an established Biometrics team in Belgium and India, Veeda is able to offer clients a full range of phase I and IIa services. In addition, Veeda maintains an extensive database of volunteers from which to accrue appropriate subjects in a timely fashion.

The BioEntrepreneur Award Presented to Apurva Shah and Binoy Gardi

clinicalresearchandcro — Tue, 02 Feb 2010 08:26:31 +0000

For emerging as a Global CRO and making Veeda a major player in the global CRO landscape Co-Group Managing Directors and Co-Founders of Veeda Clinical Research, Apurva Shah and Binoy Gardi were presented the BioEntrepreneur award at the 7th Annual Biospectrum Award ceremony held at the ITC Royal Gardenia, Bangalore.

BioSpectrum awards have been constituted to recognise contributions of companies in the Pharma and Biotech sector. The awardees are decided on the basis of a survey conducted by ‘BioSpectrum-ABLE Top 20’ conducted during June-July every year.

Establishing a global presence across Europe, India, the US and South East Asia, an average growth rate of 50% in the past 4.5 years and a unique and focused strategy are some of the reason for recognising the determination and passion of the entrepreneurial duo, said Mr. Narayan Suresh, Group Editor, Biospectrum.
“Both Binoy and I would like to thank Cybermedia (Biospectrum) for selecting us for this prestigious award and recognizing our efforts and the way we have grown Veeda by choosing a different path. The credit goes to our team in helping us realize our dream of creating a global CRO which is known for its expertise and quality in 5 short years of operation. We chose to build an organization based on a common value system that we call our Veeda DNA and that has helped us to reach such heights. In 5 years we have grown from two of us to more than 450 Veedaites working in 8 locations in 6 countries” said Shah in his acceptance speech.

for more information about this press release click here

Veeda awarded as 2009 Indian Clinical Research Company of the Year

clinicalresearchandcro — Tue, 02 Feb 2010 07:29:09 +0000

The 2009 Frost & Sullivan Award for Indian Clinical Research Company of the Year is presented to Veeda Clinical Research. The award recognizes Veeda for significant growth in the Clinical Research segment, for new offerings and for the strategy it implemented to achieve superior performance in the highly competitive Clinical Research Segment.

The Frost & Sullivan Award for Company of the Year is presented each year to the company that has demonstrated unparalleled excellence within its industry. Industry analysts compare market participants and measure performance through in-depth interviews, analysis, and extensive secondary research in order to identify best practices in the industry.

“Veeda’s significant market share in the highly competitive Phase 1 and BA/BE market in India and proven expertise in taking advantage of market changes by capturing and solidifying market presence is what caught Frost & Sullivan’s attention.” Mr. Apurva Shah, Co-Group Managing Director and Co-Founder, Veeda.

In order to select the Award recipient, Frost & Sullivan’s analysts quantify several market factors for each market participant according to predetermined criteria, paying close attention to their combined operations efforts. This process includes interviews with all the market participants, customers, and suppliers, along with extensive secondary and technology research. The companies’ efforts are then analyzed based on the number of new customers, new segments, and commitment to business expansion coupled with market growth. Industry participants are then ranked based on the predetermined measurement criteria. The Award recipient is the company that received the number one industry rank.

“Combining strategic acquisitions with focused areas of specialty, unique offerings and consistent growth are the cumulative factors for which Frost & Sullivan have considered Veeda the worthy recipient of the award”, Mr. Binoy Gardi, Co-Group Managing Director and Co-Founder, Veeda.

About Veeda Clinical Research:
Veeda Clinical Research is a leading CRO specializing in the early clinical development of drugs. With state of the art clinical pharmacology units in the UK and India, fully complaint GLP Laboratories and an established Biometrics team in Belgium and India, Veeda is able to offer clients a full range of phase I and IIa services. In addition, Veeda maintains an extensive database of volunteers from which to accrue appropriate subjects in a timely fashion.

About Veeda Oncology:
Veeda Oncology is a global Oncology CRO with operations in India, Europe and the US. The company is a full service Oncology CRO for Phase I through Phase IV studies with the unique capability of providing rapid and strong global patient accrual with an effective cost structure.